



OPEN

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

Asghar Abdoli^{1,2}, Hamidreza Jamshidi³, Mohammad Taqavian⁴, Mehdi Lari Baghal⁵ & Hasan Jalili⁶✉

Omicron variant (B.1.1.529) is able to escape from naturally acquired and vaccine-induced immunity, which mandates updating the current COVID-19 vaccines. Here, we investigated and compared the neutralising antibody induction of the ancestral variant-based BIV1-CovIran vaccine, the Omicron variant-based BIV1-CovIran Plus vaccine, and the novel bivalent vaccine candidate, BBIV1-CovIran, against the Omicron and ancestral Wuhan variants on the rat model. After inactivating the viral particles, the viruses were purified and formulated. Bivalent vaccines were a composition of 2.5 µg (5 µg total) or 5 µg (10 µg total) doses of each ancestral-based and Omicron-based monovalent vaccine. Subsequently, the potency of the monovalent and bivalent vaccines was investigated using the virus neutralisation test (VNT). The group that received three doses of the Omicron-specific vaccine demonstrated neutralisation activity against the Omicron variant with a geometric mean titer of 337.8. However, three doses of the Wuhan variant-specific vaccine could neutralise the Omicron variant at a maximum of 1/32 serum dilution. The neutralisation activity of the Omicron-specific vaccine, when administered as the booster dose after two doses of the Wuhan variant-specific vaccine, was 100% against the Omicron variant and the Wuhan variant at 1/64 and 1/128 serum dilution, respectively. Three doses of 5 µg bivalent vaccine could effectively neutralise both variants at the minimum of 1/128 serum dilution. The 10 µg bivalent vaccine at three doses showed even higher neutralisation titers: the geometric mean of 388 (95% CI 242.2–621.7) against Omicron and 445.7 (95% CI 303.3–655.0) against Wuhan. It is shown that the candidate bivalent and Omicron-specific vaccines could elicit a potent immune response against both Wuhan-Hu-1 and Omicron BA.1 variants.

The Omicron lineage of SARS-CoV-2, first described in November 2021, spread rapidly to become globally dominant and has split into many sublineages^{1,2}. With its high transmissibility and multiple novel spike (S) protein mutations, Omicron could escape from naturally acquired immunity while also challenging the effectiveness of current COVID-19 vaccines^{2,3}. According to the WHO weekly epidemiological update on COVID-19 released on 19 January 2023, globally, the Omicron variant of concern, accounted for 99.9% of reported SARS-CoV-2 viral sequences in the past 30 days⁴.

The health impacts of future SARS-CoV-2 transmission depend on evolving mitigation strategies by health systems and societies. World Health Organization has reportedly declared that vaccination strategies based on repeated booster doses are unlikely to be sustainable. In this sense, the current COVID-19 vaccines originally developed against ancestral strains may need to be updated⁵. The earliest attempts of boosting with Omicron-based vaccines had controversial results, some indicating similar efficacy to ancestral variant-based vaccine boosters in neutralising the Omicron variant⁶, while others showed a 20-fold higher neutralising titers against the Omicron variant compared to wild-type boosters⁷. Later findings indicated that bivalent vaccines containing both Omicron and ancestral strain-matched vaccines could elicit a superior neutralising antibody response against omicron and cross-reactivity with other variants, without evident safety concerns^{8,9}.

¹Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. ²Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran. ³Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴Research and Development Unit, Biosunpharmed Co, Karaj, Iran. ⁵Research and Development Unit, Shifa Pharmed Co, Karaj, Iran. ⁶Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran. ✉email: hjalili@ut.ac.ir

Since the beginning of the pandemic, Iran has endeavoured to develop and administer safe domestic vaccines, and considering the successful experiences of the country in the mass production of inactivated vaccines, applying this vaccine platform seemed the most feasible¹⁰. BIV1-CovIran is an inactivated virus vaccine developed against the Wuhan variant of SARS-CoV-2. In phase I and II clinical trials, all adverse events were mild or moderate and transient. The seroconversion rate of neutralising-antibody was 82.8% and the vaccine neutralised SARS-CoV-2 at 1/64 serum titers among 82.5% of 280 participants who received two doses of 5 µg vaccine in a 28-day interval¹⁰. In the phase III clinical trial, which is currently under peer review, a two-dose vaccine regimen was well tolerated, with no safety concerns, and conferred 70.5% and 83.1% efficacy against hospitalization and ICU admission, respectively. A historical cohort study also showed the vaccine has reduced hospitalization by 86.4% and deaths by 98.3%¹¹.

Exploiting our previous experience in constructing the Wuhan variant-based vaccine and commensurate with the global efforts in updating previous vaccines against the omicron variant, the inactivated virus vaccine platform was re-employed to develop an Omicron variant-based vaccine titled BIV1-CovIran Plus within a month of virus isolation¹². In the clinical trial study, A 5µg booster dose of the Omicron-based vaccine induced superior Omicron-specific total IgG antibody and more potent neutralisation titer compared to ancestral strain-based vaccines (neutralisation rate of 66% vs. 25% in 1/16 serum dilution).

Considering the enhanced immunogenicity and cross-reactivity shown in bivalent SARS-CoV-2 vaccines, a bivalent vaccine candidate was also developed containing an equal amount of inactivated virus particles of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (BA.1) in two doses of 5 µg (2.5 µg each) and 10 µg (5 µg each). Here, we investigated and compared the neutralising antibody induction of the ancestral variant-based BIV1-CovIran vaccine, the Omicron variant-based BIV1-CovIran Plus vaccine, and the novel bivalent vaccine candidate, BBIV1-CovIran, against the Omicron and ancestral Wuhan variants on the rat model.

Materials and methods

Overview

This study was conducted following our previous study on the preclinical evaluation of the BIV1-CovIran vaccine in the mice model¹³. Here, we conducted an animal study in the rat model to evaluate and compare the Omicron-specific vaccine (BIV1-CovIran Plus) and the bivalent vaccine (BBIV1-CovIran) with the ancestral variant-based vaccine (BIV1-CovIran) against Wuhan-Hu-1 and BA.1 SARS-CoV-2 variants. Since the construction method of Omicron-specific vaccine introduced here has not changed from the previously generated BIV1-CovIran vaccine¹³. Briefly, the Omicron variant was isolated and an inactivated vaccine was generated against it. The 5-µg and 10-µg doses of bivalent vaccine consisted of 2.5 µg or 5 µg from each of the ancestral Wuhan-Hu-1 or Omicron inactivated vaccines was also generated. Subsequently, the safety and immunogenicity of the generated vaccines against the Wuhan and Omicron variant were evaluated and compared with the ancestral-based vaccine in animal models.

Virus isolation and vaccines preparation

In the biosafety level-3 facility, the Omicron variant virus was isolated from a nasopharyngeal swab and subsequently infected mono-layer Vero cells (ATCC# CCL81). After incubation, virus growth was detected and confirmed by cytopathic effects (CPE), gene detection and electron microscopy. After passage, the viral RNAs were extracted and converted to cDNAs to be sequenced and characterized. Multiplication kinetics analysis of viral particles in Vero cells were demonstrated by TCID₅₀, 72 h post-infection.

The virus particles were inactivated by BPL (1:1400 dilution) at 2–8 °C for 20–24 h. Moreover, to eliminate the possibility of remaining live virus particles, three blind passages were done and no CPE was detected¹⁴. Finally, the inactivated viruses were purified by ultracentrifugation and chromatography and then, formulated with Alhydrogel® adjuvant 2% (Brenntag Biosector).

In this study, two types of monovalent and bivalent vaccines were prepared. The monovalent vaccines were composed of a 5 µg dose of the Wuhan-specific or the Omicron-specific vaccines. On the other hand, bivalent vaccines were a composition of 2.5 µg or 5 µg doses of each vaccine.

Animal studies

Nine groups of five female, eight weeks old Wistar rat models provided by the Laboratory Animal Science Department, Pasteur Institute of Iran, Karaj, Iran were prepared. A total of 45 rats were divided into nine groups (each containing 5 rats). Some groups received two doses of vaccines on days 0 and 28, while others received three doses on days 0, 28, and 56. A detailed description of the study groups stratified by the vaccine they had been received is demonstrated in Table 1. All animal studies were conducted under the approval of animal ethics committee guidelines of the Ministry of Health and Medical Education (Tehran, Iran; ethical code: IR.ACECR.IBCRC.REC.1399.016), and were performed according to the ARRIVE guidelines. A special effort was made to keep to a minimum necessary the number of animals to achieve adequate significance.

Virus neutralisation test

The conventional virus neutralising test (cVNT) was conducted on sera acquired from rat groups^{15–17}. The heat-inactivated sera were mixed with Omicron and Wuhan variants of SARS-CoV-2 in the Dulbecco's Modified Eagle Medium (DMEM). The mixtures were then inoculated onto Vero cells in 96-well plates and the supernatants (containing neutralising antibodies) were removed at one hour post infection. The infected Vero cells were kept in DMEM and incubated for 48 h at 37 °C in a 5% CO₂ incubator. CPEs were recorded under microscopes 72 h post-infection and the neutralising antibody titers were measured as values of the highest dilution that inhibited CPE formation in each well.

Group	Vaccine	Number of doses	Days of injection
WW	BIV1-CovIran (monovalent ancestral-based)	2	0–28
OO	BIV1-CovIran Plus (monovalent Omicron-based)	2	0–28
WWW	BIV1-CovIran	3	0–28–56
OOO	BIV1-CovIran Plus	3	0–28–56
WWO	2xBIV1-CovIran + 1xBIV1-CovIran Plus	3	0–28–56
BB (2.5)	BBIV1-CovIran (bivalent vaccine: 2.5 µg + 2.5 µg)	2	0–28
BB (5)	BBIV1-CovIran (bivalent vaccine: 5 µg + 5 µg)	2	0–28
BBB (2.5)	BBIV1-CovIran (2.5 µg + 2.5 µg)	3	0–28–56
BBB (5)	BBIV1-CovIran (5 µg + 5 µg)	3	0–28–56

Table 1. The vaccine type, dose numbers, and the days of injection among study groups.

Statistical analysis

The VNTs were summarized as geometric mean with 95% confidence interval (95% CI). To assess the statistical significance of the differences in VNTs between any two groups Mann–Whitney U test was performed. This non-parametric test was chosen due to the non-normal distribution of the data. A significance level of $\alpha = 0.05$ was selected as the threshold for determining statistical significance.

Ethical approval

All animal models and maintenance procedures were under the approval of animal ethics committee guidelines of the Ministry of Health and Medical Education (Tehran, Iran; ethical code: IR.ACECR.IBCRC.REC.1399.016), and were performed according to the ARRIVE guidelines (<https://arriveguidelines.org>). All methods were carried out in accordance with relevant guidelines and regulations.

Results

Viral particles successfully infected the Vero cells to prepare the vaccine seed

The Variant of Concern (VOC) Omicron GRA (B.1.1.529 + BA) SARS-CoV-2 strain was successfully isolated in Vero cells from the clinical specimen. The isolated strain had more than 99.9% identity to the original Omicron variant. Multiplication kinetics analysis of viral particles in Vero cells demonstrated the peak of multiplication with 10^6 TCID₅₀, 72 h post-infection (Fig. 1A). After four passages, the vaccine seed was prepared, and the virus growth was recorded by the presence of CPE (Fig. 1B,C).

The monovalent Omicron-specific vaccine demonstrated neutralisation activity against the Omicron at various dose intervals

Among five rats that received two doses of the Omicron-specific on days 0 and 28, four of them (80%) demonstrated neutralisation activity against the Omicron variant at the 1/128 dilution (Fig. 2B). On the other hand, two doses of Wuhan-specific could neutralise the Omicron variant at maximum 1/8 serum dilution (i.e., geometric mean: 97 vs. 7 against Omicron, P value < 0.01) (Fig. 3). All of the samples' sera (100%) in OO group neutralised the Wuhan variant at the 1/16 dilution (Fig. 2A). In addition, among samples that received three doses of Omicron-specific on days 0, 28, and 56, the maximum dilution that successfully neutralised the Omicron variant was 1/512. Indeed, 3 out of five rats (60%) at 1/256 and 2 out of five (40%) at 1/512 sera dilution demonstrated neutralisation activity (Fig. 2C). Three doses of Omicron-specific were also able to neutralise the Wuhan variant at 1/32 (80%) and 1/64 (20%) dilutions (Fig. 2D). We also examined the neutralisation activity of the Omicron-specific vaccine when administered as the booster dose on day 56 after two doses of original the Wuhan-specific vaccine (i.e., BIV1-CovIran) on days 0 and 28. In this group, all five samples (100%) neutralised the Omicron variant and the Wuhan variant at 1/64 and 1/128 serum dilution, respectively (Fig. 2C,D). The neutralisation potency in this group was also higher than three doses of Wuhan-specific vaccine against the Omicron variant (i.e., geometric mean: 64 vs. 27.9, P -value < 0.01) (Fig. 3).

The bivalent vaccine demonstrated neutralisation activity against both the Omicron and the Wuhan variants

Two different doses (i.e., 2.5 and 5 µg) of the Omicron-specific and the Wuhan-specific vaccines were mixed and injected into rats two or three times at 28-day intervals. The first group that had received two doses of the bivalent vaccine consisting of 2.5 µg from each vaccine on days 0 and 28 demonstrated similar neutralising activity against both variants (Fig. 2). Accordingly, the sera of three rats (60%) could neutralise both the Omicron and Wuhan variants at 1/128 dilution, and the other two (40%) had neutralising activity at 1/64 serum dilution (i.e., geometric mean: 97, 95% CI 60.5–155.4) (Figs. 2C,D, 3). When it came to the group that had received two doses of bivalent made from 5 µg of each vaccine, the minimum neutralising serum dilution was 1/128. 80% of the samples' sera in this group neutralised the Omicron variant at 1/128 dilution, and 20% neutralised it at 1/256 (i.e., geometric mean: 147, 95% CI 100.1–216.1) (Figs. 2A,B, 3). On the other hand, 60% of them neutralised the Wuhan variant at 1/128 and 40% at 1/256 serum dilutions (i.e., geometric mean: 168.9, 95% CI 105.4–270.6). However, the




Figure 1. Virus growth curve and infection. (A) The virus growth curve analyzed by TCID₅₀, (B) positive CPE resulting from virus infection, (C) CPE in the control sample.

difference of VNT titers between 10 and 5 μ g vaccine regimens did not reach significance threshold against either Wuhan (P -value = 0.075) or Omicron variants (P -value = 0.121).

Finally, when we tried three doses of the bivalent vaccines on days 0, 28, and 56, the neutralising potency of sera was approximately one-fold increased (Fig. 3). Four out of five rats (80%) that had received three doses of the 2.5 μ g mixture demonstrated neutralising activity against both the Omicron and the Wuhan variants at 1/256 serum dilution, and the other one at 1/512 dilution (i.e., geometric mean: 222.9, 95% CI 151.7–327.5) (Fig. 2C,D). Therefore, the three dose regimen of 2.5 μ g mixture demonstrated significantly higher titers than the two-dose regimen (P -value < 0.05). In the last group, three doses of 5 μ g mixture were tested and the maximum neutralising serum dilution was 1/256. In this group, 60% and 80% of the samples' sera could neutralise the Omicron and Wuhan variants, respectively at 1/512 dilution (i.e., the geometric mean of 445.7 (95% CI 303.3–655.0) against Wuhan; and 388 (95% CI 242.2–621.7) against Omicron) (Figs. 2C,D, 3). Therefore, the VNT titers were significantly higher in the three dose regimen of 5 μ g mixture than the two-dose regimen (P -value < 0.05).

Discussion

Omicron is associated with a marked ability of reinfection or breakthrough infection even in populations with wide vaccine coverage, benefiting from its heavily altered antigenicity^{1,18}. Since the identification of the variant, evidence prompted the need for developing Omicron-specific vaccines⁷. Recent Omicron sublineages, BA.4/5, are currently causing most cases of COVID-19 in many countries, and have been shown to resist even more than BA.1 and BA.2 against neutralisation by triple-dosed vaccinee serums¹⁹. It is evident that protection against symptomatic BA.4/5 reinfection in those with a previous pre-omicron SARS-CoV-2 infection was 35.5%, while in those with a history of infection with a post-Omicron subvariant (including BA.1 or BA.2), the protection was 76.2%²⁰. This highlights the role of prior exposure to Omicron subvariants in having high protection against the BA.4/5²¹. The BQ and XBB subvariants, which are now rapidly expanding, are shown to further compromise the efficacy of current COVID-19 vaccines. The three shots of the ancestral-based vaccine showed far lower neutralization titers against BQ.1, BQ.1.1, XBB, and XBB.1 compared to the ancestral strain, with reductions of >37-fold to >71-fold. The variants also showed alarmingly high resistance to neutralization by serum of persons recently boosted with the new bivalent (covering BA.5) mRNA vaccines²². Nonetheless, CDC data showed bivalent booster doses provided 73% additional protection against COVID-19 hospitalization compared to the ancestral-based monovalent vaccine through September–November 2022 when BQ.1 was circulating in the US²³.

To date (as of January 21, 2023), more than 13.2 billion doses of vaccine have been delivered to people, and 5.52 billion people, i.e. 69.3% of the global population, received at least one dose of COVID-19 vaccine (Our World in Data; Coronavirus (COVID-19) Vaccinations). However, almost all those vaccines were designed based




Figure 3. The VNT results' geometric means. The geometric means of the neutralisation activity of study groups against the Omicron and Wuhan variants. WW: Two doses of BIV1-CovIran; OO: Two doses of BIV1-CovIran Plus; WWW: Three doses of BIV1-CovIran; OOO: Three doses of BIV1-CovIran Plus; WWO: BIV1-CovIran Plus booster after two doses of BIV1-CovIran; BB (2.5): Two doses of 5 µg BBIV1-CovIran; BB (5): Two doses of 10 µg BBIV1-CovIran; BBB (2.5): Three doses of 5 µg BBIV1-CovIran; BBB (5): Three doses of 10 µg BBIV1-CovIran.

to the current circulating SARS-CoV-2 subvariants, and makes the immune system responses compatible with the circulating epitopes. The updated vaccines could also be applicable in immunologically naïve populations, such as children who reach the age of eligibility for getting COVID-19 vaccines⁶.

On the other hand, viral evolution continues and escape variants emerge, vaccine neutralization potency against multiple variants is highly desirable⁸. In this study, the bivalent vaccine, without sacrificing potency against the Wuhan variant, achieved significantly higher neutralising titers against Omicron than the ancestral-based vaccine. Two doses of 5 µg bivalent vaccine (2.5 µg each) neutralised both Omicron and Wuhan variants by the geometric mean titer of 97. Interestingly, the titer against Omicron equals the titer elicited by two doses of the Omicron-based vaccine and is 13-fold higher than the titer elicited by two doses of the Wuhan-based vaccine. Delivering the third dose of bivalent vaccine increased the titer by more than twofolds for both Omicron and Wuhan variants. Moreover, delivering the 10 µg bivalent vaccine (5 µg each) resulted in even higher neutralisation titers against Omicron and Wuhan variants in both two-dose and three-dose regimens. The broad neutralising antibody response shown in this study is in accordance with findings from bivalent vaccine boosters of Moderna in preclinical studies²⁵. The bivalent Omicron-containing vaccine candidate of Moderna not only elicited higher spike-binding antibody responses against omicron BA.1 than mRNA-1273 (based on ancestral strain) but also showed a superior response against BA.4/5 subvariants and ancestral Wuhan-1 variant.

Studies demonstrated that updated vaccines targeting Omicron BA.1 can induce broadly cross-protective neutralizing antibody responses against diverse SARS-CoV-2 variants without sacrificing immunity to the ancestral strain²⁶. However, the preference between the monovalent and bivalent updated vaccines has remained an ongoing debate. Some studies recommend that updated monovalent vaccines are nearly equivalent to bivalent

vaccines for neutralization of Omicron subvariants (BA.1 and BA.4/5); therefore, suggest that monovalent variant vaccines could replace bivalent vaccines as the updated boost²⁶. On the contrary, some studies show boosting with variant-matched bivalent vaccines expands both cross-reactive and type-specific clones, and neutralizing antibodies are produced from each clone against the variant spike protein²⁷. The studies indicate that boosting with bivalent vaccines are a feasible approach for extending the coverage of vaccines for emerging and co-circulating SARS-CoV-2 variants^{28,29}. Continued monitoring of neutralization and real-world vaccine effectiveness data are needed to set a preference policy between updated SARS-CoV-2 monovalent and bivalent vaccine boosters.

This study is subjected to some limitations. First, the study evaluated neutralization titers against the Wuhan-Hu-1 and BA.1 sublineage, which were the sublineages that their inactivated particles were inserted in the vaccines. Nevertheless, the neutralization potency of the vaccines against other circulating subvariants such as BA.2, BQ.1, and XBB.1 remained unexplored, since the variants were not accessible for the research team by the time that the study was conducted. Therefore, the potential of the vaccines to induce a cross-protective antibody response was not documented. However, the prospering preclinical and real-world results of the Wuhan variant-based (BIV1-CovIran) against pre-Omicron variants, combined with the high anti-Omicron neutralization titers elicited by the Omicron-based vaccine (BIV1-CovIran Plus), would be a promise that the bivalent candidate may enhance immunity against all currently circulating variants^{11,13}. As the second limitation, non-neutralizing antibodies and cross-reactive T-cell responses, both of which could influence protective immunity, were not taken into account in our analysis³⁰. Future experiments using other circulating and emerging strains and evaluating other components of immune system may be informative to determine the breadth of the vaccine protection.

Immunity induced by existing COVID-19 vaccines is subjected to waning over time^{31,32}, which in the case of the Omicron is particularly concerning since it is coupled with the variant's ability to escape the humoral immune response elicited by ancestral variant-based vaccines^{33,34}. Altogether, the study iterates that the population's waning immunity against SARS-CoV-2 should be recovered using Omicron-specific vaccines. This is especially important for Iran's case, in which the new peak of COVID-19 caused by BA.2, BQ.1, and XBB was officially declared by the ministry of health on December 30, 2022³⁵. Our findings indicate that Omicron-specific and bivalent vaccines may be a new tool in response to emerging variants, conserving neutralisation potency against Omicron sublineages. Accordingly, we are planning to evaluate the Omicron-based and bivalent vaccines according to the latest FDA guidance on the emergency use authorization for COVID-19 vaccines³⁶.

Data availability

All datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request. The isolated virus sequence data are available in the GISAID repository [ACCESSION NUMBER: EPI_ISL_7845314, ACCESS LINK: <https://www.epicov.org/epi3/frontend#e66db>].

Received: 27 March 2023; Accepted: 26 December 2023

Published online: 02 January 2024

References

- Collie, S., Champion, J., Moultrie, H., Bekker, L.-G. & Gray, G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. *N. Engl. J. Med.* **386**, 494–496 (2021).
- Tseng, H. F. *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat. Med.* **28**, 1063–1071 (2022).
- Bok, K., Sitar, S., Graham, B. S. & Mascola, J. R. Accelerated COVID-19 vaccine development: Milestones, lessons, and prospects. *Immunity* **54**, 1636–1651 (2021).
- World Health Organization. *Weekly epidemiological update on COVID-19*. (2023).
- WHO. *Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)*, accessed 2 February 2022; <https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition> (2022)
- Gagne, M. *et al.* mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. *Cell* **185**, 1556–1571.e18 (2022).
- Fang, Z. *et al.* Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. *Nat. Commun.* **13**, 1–12 (2022).
- Chalkias, S. *et al.* A bivalent omicron-containing booster vaccine against Covid-19. *N. Engl. J. Med.* https://doi.org/10.1056/NEJMOA2208343/SUPPL_FILE/NEJMOA2208343_DATA-SHARING.PDF (2022).
- Lee, I.-J. *et al.* A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. *J. Biomed. Sci.* **29**, 49 (2022).
- Mohraz, M. *et al.* Original research: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: Findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. *BMJ Open* **12**, e056872 (2022).
- Mirahmadizadeh, A. *et al.* Effectiveness of Coronavirus Disease 2019 vaccines in preventing infection, hospital admission, and death: A historical cohort study using Iranian registration data during vaccination program. *Open Forum Infect. Dis.* **9**, ofac177 (2022).
- Mohraz, M. *et al.* Immunogenicity and safety of a variant-specific COVID-19 vaccine booster, BIV1-CovIran Plus: Findings from a non-inferiority, parallel-design non-randomised clinical trial (2022).
- Abdoli, A. *et al.* Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study. *Rev. Med. Virol.* **32**, e2305 (2022).
- World Health Organization. *Recommendations for the production and control of poliomyelitis vaccine (oral)*. WHO Tech. Rep. Ser. (2002).
- van Tol, S. *et al.* Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. *Emerg. Microbes Infect.* **9**, 1965–1973 (2020).
- Meyer, B. *et al.* Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). *Emerg. Microbes Infect.* **9**, 2394–2403. <https://doi.org/10.1080/22221751.2020.1835448> (2020).
- Rijkers, G. *et al.* Differences in antibody kinetics and functionality between severe and mild severe acute respiratory syndrome Coronavirus 2 infections. *J. Infect. Dis.* **222**, 1265–1269 (2020).

18. Pulliam, J. R. C. *et al.* Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. *Science* **376**, eabn4947 (2022).
19. Tuekprakhon, A. *et al.* Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell* **185**, 2422–2433.e13 (2022).
20. Altarawneh, H. N. *et al.* Protective effect of previous SARS-CoV-2 infection against Omicron BA.4 and BA.5 Subvariants. *N. Engl. J. Med.* **387**, 1620–1622 (2022).
21. Hansen, C. H. *et al.* Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: A nationwide population-based study in Denmark. *Lancet Infect. Dis.* **23**(2), 167 (2022).
22. Wang, Q. *et al.* Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell* <https://doi.org/10.1016/j.cell.2022.12.018> (2022).
23. Surie, D. *et al.* Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19—Associated hospitalization among immunocompetent adults aged ≥ 65 years—IVY Network, 18 States, September 8–November 30, 2022. *MMWR. Morb. Mortal. Wkly. Rep.* **71**, 1625–1630 (2022).
24. Fauci. Omicron-specific vaccines 'prudent' but may be unnecessary | *TheHill*, accessed 28 January 2022; <https://thehill.com/policy/healthcare/591241-fauci-omicron-specific-vaccines-prudent-but-may-be-unnecessary>. (2022)
25. Scheaffer, S. M. *et al.* Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. *Nat. Med.* <https://doi.org/10.1038/s41591-022-02092-8> (2022).
26. Branche, A. R. *et al.* Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. *Nat. Med.* **29**, 2334–2346 (2023).
27. Scheaffer, S. M. *et al.* Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. *Nat. Med.* **29**, 247–257 (2023).
28. Corleis, B. *et al.* Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models. *Nat. Commun.* **14**, 816 (2023).
29. Chalkias, S. *et al.* Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: Phase 2/3 trial interim results. *Nat. Med.* **29**, 2325–2333 (2023).
30. Errico, J. M., Adams, L. J. & Fremont, D. H. Antibody-mediated immunity to SARS-CoV-2 spike. *Adv. Immunol.* **154**, 1–69 (2022).
31. Levin, E. G. *et al.* Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N. Engl. J. Med.* **385**, e84 (2021).
32. Doria-Rose, N. *et al.* Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. *N. Engl. J. Med.* **384**, 2259–2261 (2021).
33. Cao, Y. *et al.* Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* **602**, 657–663 (2022).
34. Planas, D. *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* **602**, 671–675 (2022).
35. Financial Tribune. *Medical Community on High Alert to Tackle New Covid Wave.* <https://financialtribune.com/node/116667> (2023).
36. Food and Drug Administration. *Emergency Use Authorization for Vaccines to Prevent COVID-19* 1–31 (2022).

Author contributions

Conceptualization: A.A., Hamidreza J., M.T., M.L.B., Hassan J.; Data curation: A.A., M.T.; Formal Analysis: A.A., M.T.; Funding acquisition: A.A., M.T.; Investigation: Hamidreza J., Hassan J.; Methodology: A.A., M.T., Hassan J.; Project administration: Hassan J.; Resources: Hassan J., Hamidreza J.; Supervision: Hassan J., Hamidreza J.; Validation: Hassan J., Hamidreza J.; Writing – original draft: A.A.; Writing – review & editing: A.A., Hamidreza J., M.T., M.L.B., Hassan J.

Funding

Shifa-Pharmed Industrial Group.

Competing interests

Mohammad Taqavian and Mehdi Lari Baghal are employees of Shifa Pharmed, with no stock options or incentives. Hamidreza Jamshidi and Hasan Jalili are the chairmen and managing directors of the vaccine project in Shifa Pharmed, respectively. Asghar Abdoli is the founder and scientific director of Amirabad Virology Lab.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-50822-w>.

Correspondence and requests for materials should be addressed to H.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024